What is Empagliflozin-metformin?
Empagliflozin-Metformin is an oral antidiabetic combination medication, specifically designed for the treatment of type 2 diabetes. It combines empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps reduce blood sugar levels by preventing glucose reabsorption in the kidneys, with metformin, a biguanide that works by decreasing glucose production in the liver and improving insulin sensitivity. This dual-action combination is intended to lower fasting plasma glucose, HbA1c, and improve glycemic control while also offering potential cardiovascular benefits.
What is Empagliflozin-metformin used for?
Empagliflozin-Metformin, also known as Steglatro, is an oral anti-diabetic medication used in the treatment of type 2 diabetes. It is a fixed-dose combination product containing Empagliflozin and Metformin as its active ingredients.
Empagliflozin is a selective SGLT1/2 inhibitor that works by increasing glucose excretion through the urine, thereby reducing blood glucose levels. This mechanism of action helps to improve glycemic control in patients with type 2 diabetes. On the other hand, Metformin is a biguanide that acts by decreasing glucose production in the liver and increasing insulin sensitivity.
The combination of Empagliflozin and Metformin provides dual mechanisms of action for glycemic control. By inhibiting SGLT1/2 and reducing hepatic glucose output, this fixed-dose combination product enhances insulin secretion and reduces hyperglycemia in patients with type 2 diabetes.
Empagliflozin-metformin side effects
- Increased risk of ketoacidosis
- Increased risk of fractures (particularly in postmenopausal women and patients with a history of bone fractures)
- Pancreatitis
- Hypoglycemia (with insulin or other antidiabetic agents)
- Urinary tract infections
- Genital amputations
- Hypersensitivity reactions (e.g., angioedema, anaphylaxis)
- Increased risk of acute kidney injury (in patients with severe renal impairment)
- Increased risk of necrotizing fasciplitis of the perineum (Fournier’s gangrene)
- Increased risk of amputations (including surgical corrections or revisions)
- Increased risk of serious skin and soft tissue infections
Disclaimer
The content on this website is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The information provided here is based on general research and may not apply to individual circumstances. We do not guarantee the accuracy or completeness of any content on this website. Always consult with a healthcare professional before making any changes to your medication or health routine.